Obesity, Type 2 Diabetes and Bone {#Sec1}
=================================

Obesity is a major and growing public health problem; for example, in the UK, 40% of adults will be obese by 2025 \[[@CR1]\]. Obesity is the most important risk factor for type 2 diabetes (T2DM), and the global prevalence of T2DM is likely to be 592 million by 2035 \[[@CR2]\]. As the population ages, the burden of osteoporosis and fragility fracture also increases. Obesity and T2DM have effects on fracture risk, and fractures in T2DM are associated with greater morbidity than in the general population. Understanding how to assess and treat fracture risk in these groups is important for health care planning and individual patients. Additionally, the study of the mechanisms of action of obesity and T2DM on bone has already offered insights that may be applicable in the broader study of osteoporosis, such as the effects of adipokines on bone cells and the effects of collagen glycation on material properties of bone. There are some similarities in the effect of obesity and T2DM on bone, but some important differences such as cortical porosity and collagen glycation.

In this review, we describe the effects of obesity and T2DM on fracture risk and discuss possible mechanisms of their effects. We also consider the validity of existing fracture risk prediction tools and efficacy of osteoporosis treatment in these patient groups.

Obesity, Fracture and BMD {#Sec2}
=========================

Most of the available evidence supports a lower risk of proximal femur and vertebral fracture in obese adults \[[@CR3]\]. However, fracture risk in obesity is not lower at all skeletal sites; the risk of some non-spine fractures including proximal humerus (RR 1.28), upper leg (OR 1.7) and ankle fracture (OR 1.5) is higher \[[@CR4], [@CR5]\]. A large number of low-trauma fractures occur in overweight and obese men and women, and the prevalence of low-trauma fractures is similar in obese and non-obese women \[[@CR6]\]. Therefore, obesity is not entirely protective against fracture, and there are some site-specific effects on fracture.

There is a positive association between body mass index (BMI) and bone mineral density (BMD) \[[@CR7]\]. BMD by dual-energy X-ray absorptiometry (DXA) is higher in obese people, but higher BMI and soft tissue thickness cause error in DXA measurement \[[@CR8]\] through assumptions about abdominal thickness and beam hardening effects. However, other quantitative imaging methods (CT and ultrasound) also support higher BMD by DXA (although other methods are also subject to some influence from surrounding soft tissue). Calcaneus bone stiffness by ultrasound is greater in obesity \[[@CR9]\] and by high-resolution peripheral quantitative computed tomography (HR-pQCT), obese adults have higher BMD, higher cortical BMD, higher trabecular BMD and greater trabecular number at the distal radius and distal tibia \[[@CR10], [@CR11]\]. Radius and tibia strength estimated by finite element analysis from HR-pQCT is greater in obesity than in normal weight controls \[[@CR10]\]. Therefore, BMD probably is truly higher in obesity, and there is no site-specific BMD deficit to explain the site-specific fracture risk.

It is possible that even if BMD increases in response to obesity, the capacity for increase is limited and eventually the load-to-strength ratio rises far enough to cause fracture in low-trauma injuries. The increase in radius and tibia strength by HR-pQCT in obesity is proportionally less than the increase in BMI \[[@CR11]\]. At the hip, by QCT and DXA, obese people have favourable features for bone strength, but the load-to-strength ratio is greater than normal weight controls \[[@CR12], [@CR13]\]. Greater soft-tissue thickness over the lateral hip dissipates fall impact, and so may continue to protect against hip fracture at high body weight even when load-to-strength ratio is exceeded \[[@CR12], [@CR14]\]. Intramuscular fat content is increased in obesity, and may be associated with poorer muscle function and increased fracture risk ('dynapenic obesity') \[[@CR15], [@CR16]\]. Poorer muscle function could increase falls and injury when falling, and there are data showing an excess of falls in obese people \[[@CR17]\].

Thus, although BMD is higher in obesity, it may not be increased sufficiently to resist the greater forces acting when obese people fall. Non-bone factors such as muscle function and soft tissue thickness should also be considered as contributory and protective factors.

Mechanisms of Action of Obesity on Bone {#Sec3}
=======================================

Some insight into how obesity may exert effects on bone can be obtained from biochemical markers of bone turnover. Biochemical markers are lower in obesity than in normal weight \[[@CR18]\], but the difference in resorption markers may be greater than the difference in formation markers. This results in a higher uncoupling index in obesity, suggesting positive bone balance which helps to maintain bone mass in adulthood and with ageing \[[@CR10]\]. Menopause causes a rapid increase in bone turnover, with net higher bone resorption and negative bone balance leading to bone loss. Higher body weight is associated with slower menopausal bone loss \[[@CR19]\] consistent with a tendency towards positive bone balance in obesity.

One possible mechanism for higher BMD in obesity is increased mechanical loading and strain. Obese adults have increased body fat mass, but also increased lean mass, so passive loading and muscle-induced strain may have effects on bone modelling, density and geometry. However, impaired muscle function due to intramuscular fat accumulation could attenuate the positive effects of increased muscle mass on bone. If the dominant mechanism acting to increase BMD were physical loading, an increase in bone size by periosteal apposition might be expected. Hip cross-sectional area by DXA and QCT is increased in obesity \[[@CR12], [@CR13]\], but bone size at the radius and tibia by HR-pQCT does not differ between obese and normal weight controls \[[@CR10]\]. Therefore, loading probably does not explain all of the action of obesity on bone.

Obesity has effects on a number of hormones known to act on bone, and so may act on bone through endocrine pathways. Adipocytes produce endocrine factors shown to influence bone cell number and activity. Leptin is produced by adipocytes, and circulating leptin levels reflect body fat mass with a primary role to regulate long-term energy balance by signalling satiety in the hypothalamus and reducing food intake. Circulating leptin acts on bone cells directly to increase bone formation \[[@CR20]\], but when acting through the hypothalamus, it may inhibit bone formation through increased activation of the sympathetic nervous system \[[@CR21]\]. The evidence from clinical human studies suggests that the dominant effect in vivo is probably the peripheral action to increase BMD \[[@CR22]\]. Adiponectin is secreted in inverse proportion to fat mass, and has roles in the regulation of glucose and lipid metabolism. In humans, circulating adiponectin levels are inversely related to BMD \[[@CR23]\]. Osteoclasts and osteoblasts express adiponectin receptors, and there is some experimental evidence that adiponectin could modulate RANK/RANK-ligand/OPG signalling \[[@CR24]\]. Similarly to leptin, mouse studies suggest that adiponectin may also signal through the central nervous system to regulate bone turnover through autonomic innervation \[[@CR25]\]. However, the dominant mechanism through which it acts on the skeleton in obese humans in vivo is not yet clear. Adipocytes express aromatase, and aromatisation of androgens is the main source of oestrogen in postmenopausal women and men. High fat mass is associated with higher circulating estradiol, and so aromatase activity is likely to contribute to positive effects of fat on bone, particularly in postmenopausal women \[[@CR26]\].

Pancreatic and gut hormone secretion is altered in obesity and may influence bone metabolism. Insulin, amylin and preptin are increased in obesity, and may have direct effects on bone cells to increase bone formation and decrease resorption. Insulin may also have indirect positive effects on bone by decreasing hepatic sex-hormone binding globulin production, increasing bioavailability of oestrogen and androgens. Ghrelin, gastric inhibitory polypeptide (GIP) and glucagon-like peptide 2 (GLP-2) have direct and indirect effects on bone metabolism, driven by the acute response to food intake and more long-term energy balance \[[@CR27]\].

Serum 25-hydroxy vitamin D (25OHD) is lower in obesity than normal weight controls, but this is likely to reflect greater volume of distribution (into fat, muscle and extracellular fluid). Therefore, serum 25OHD may not indicate low whole-body vitamin D status in obesity, and it does not seem to be associated with lower BMD or higher bone turnover. It is possible that the lower vitamin D in obesity would adversely affect BMD, but that the other positive effects of obesity on BMD are dominant \[[@CR28]\].

Not all fat is the same, and some fat depots could have negative effects on bone (Fig. [1](#Fig1){ref-type="fig"}). Subcutaneous and visceral fat have different metabolic profiles, and pro-inflammatory cytokines from visceral fat such as interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-α) increase bone resorption, so may have harmful effects on BMD \[[@CR29]\]. In support of adverse actions, greater central and visceral adiposity is associated with lower BMD and some adverse microstructural features from bone biopsy and HR-pQCT but the relationship may vary with age and gender \[[@CR30]--[@CR32]\].

Fig. 1Fat depot actions on bone in obesity

Fracture Risk Assessment and Osteoporosis Treatment in Obesity {#Sec4}
==============================================================

Fracture risk assessment in clinical practice uses bone densitometry by DXA and clinical risk factors. This offers some challenges in obesity---the precision of DXA measurements is reduced in obesity due to effects of soft tissue thickness \[[@CR8]\]. Also, because fracture pattern differs between obese and normal weight groups, and we do not yet fully understand the cause of fractures in obesity, the usual fracture prediction tools might not be expected to perform so well. However, FRAX (with and without BMD) predicted hip and major osteoporotic fracture with similar accuracy in obese and non-obese postmenopausal women in the Study of Osteoporotic Fractures \[[@CR33]\].

Most currently used drugs for osteoporosis are anti-resorptive. Because bone turnover and bone resorption are already reduced in obesity, the question has been raised whether anti-resorptive treatment is effective for fracture prevention in obesity. The key clinical trials of bisphosphonates did not include large numbers of obese people, but there are some available data. In the Horizon trial, 3 years of zoledronic acid decreased vertebral fracture more in postmenopausal women with BMI above 25 kg/m^2^ than women with BMI below 25 kg/m^2^ \[[@CR34]\]. Non-vertebral fracture reduction did not differ by BMI. In the Freedom trial, with 3 years of denosumab, vertebral fracture risk reduction was independent of BMI, but non-vertebral fracture reduction was not significant in women with BMI above 25 kg/m^2^ \[[@CR35]\].

Type 2 Diabetes, Fracture and BMD {#Sec5}
=================================

A number of meta-analyses have reported an increase in the risk of fractures in type 2 diabetes (T2DM) \[[@CR36]--[@CR40]\]. There is a 1.3- to 2.1-fold increased risk of hip fracture \[[@CR36], [@CR37], [@CR39], [@CR40]\] and 1.2-fold increased risk of other fractures \[[@CR36], [@CR37]\], but vertebral fracture risk does not seem to be increased \[[@CR37], [@CR40]\] (Table [1](#Tab1){ref-type="table"}). The size of the fracture risk increase may be modest, but it is important to recognise that after fracture, patients with diabetes have greater mortality, develop more complications (such as renal impairment and cardiac problems) and recover less well than non-diabetic patients \[[@CR41], [@CR42]\].

Table 1Risk of hip, spine and other any fractures in T2DM according to meta-analysesStudyHip fracturesSpine fracturesOther fracturesJanghorbani \[[@CR32]\]1.7 (1.3--2.2)\*1.2 (0.7--2.2)Any fracture 1.2 (1.01--1.5)\*Vestergaard \[[@CR33]\]1.38 (1.25--1.53)\*0.93 (0.63--1.37)Any fractures 1.19 (1.11--1.27)\*Fan \[[@CR35]\]2.07 (1.83--2.33)\*----Dytfeld \[[@CR36]\]1.26 (1.07--1.57)\*1.13 (0.94--1.37)--\*Statistically significant increase in the risk

Although fracture risk is higher, BMD is increased in T2DM (lumbar spine *Z*-score + 0.41, total hip *Z*-score + 0.27) \[[@CR37]\]. Nearly all people with T2DM are obese, and so the higher BMD in T2DM is probably due to similar mechanisms as those acting in non-diabetic obese people. In addition, high circulating insulin could increase osteoblast activity and bone formation \[[@CR43]\]. The increase in foot and ankle fractures is consistent with the pattern seen in obesity, but the increase in hip fracture risk is discrepant between T2DM and non-diabetic obese, so additional factors may be acting to increase bone fragility in T2DM.

Microarchitecture studies with HR-pQCT suggest a cortical strength deficit in T2DM. There is decreased cortical thickness and volumetric BMD (vBMD), with increased cortical porosity and pore size in T2DM \[[@CR44]\] patients with microvascular disease (retinopathy, neuropathy or nephropathy). These changes are associated with decreased bone strength by finite element analysis \[[@CR44], [@CR45]\] and are greater in T2DM patients with previous fractures \[[@CR46]\], suggesting that they may be clinically significant contributors to fracture risk.

Mechanisms of Action of T2DM on Bone {#Sec6}
====================================

Bone turnover markers studies in diabetes have had some conflicting results, but the most consistent finding is that markers of resorption (C-terminal cross-linking telopeptide of type I collagen (CTX), N-terminal cross-linking telopeptide of type I collagen (NTX)) and formation (procollagen type I N propeptide (P1NP), osteocalcin) are reduced \[[@CR47], [@CR48]\]. Methodological studies have excluded a direct effect of glucose in the measurements \[[@CR48]\], so the bone turnover markers probably do reflect a true biological effect. Histomorphometry in T2D shows decrease in bone volume, osteoid volume, thickness and osteoblast surface, and poor uptake of label indicating reduced bone formation \[[@CR49], [@CR50]\] consistent with lower turnover from biochemical markers.

One important factor which may contribute to bone fragility in T2DM is post-translational glycation of collagen in bone matrix. Enzymatic cross-linking of collagen maintains the strength of normal bone matrix because the collagen matrix confers toughness, allowing the bone to endure plastic strain without breaking. Increasing numbers of cross-links reduces the plasticity of the matrix, and the bone breaks at lower strain. Older collagen has more cross-links and less plasticity. Exposure to high glucose levels promotes glycation of proteins \[advanced glycation end products (AGEs)\]. In collagen, AGEs lead to non-enzymatic cross-linking \[[@CR51]\], and so could decrease plasticity and bone material strength \[[@CR52]\]. Higher urine pentosidine (a marker of AGEs) is associated with higher vertebral fracture risk in post-menopausal non-diabetic women \[[@CR53]\].

Bone material strength can be evaluated in vivo by reference point indentation (Osteoprobe). By this method, material strength is 10% lower in T2DM than matched controls. The difference persists after correction for BMI and is correlated with average HbA1c \[[@CR54]\]. Indirect measurement of AGEs using skin auto fluorescence explains 26% of the reduced bone strength by indentation, and is associated with lower P1NP in patients with T2D \[[@CR55]\]. Therefore, there is some evidence for an association of glucose exposure with poor bone material quality in T2DM, and collagen glycation is a plausible contributor to increased fracture risk.

Particularly for foot and ankle fracture, it is possible that neuropathy and vasculopathy in T2DM could have effects on bone cell function or bone material properties. Sympthetic tone contributes to the regulation of bone turnover, and the extreme example of Charcot foot demonstrates the potential for bone to dysfunction when normal sensory and autonomic innervation is lost. However, these factors have not yet been investigated in the context of diabetes and fracture. Besides the intrinsic bone properties, other factors could increase the risk of fractures in T2DM. Poor metabolic control, hypoglycaemia and neuropathy increase falls risk \[[@CR56], [@CR57]\], and in meta-analysis, hypoglycaemia was associated with fracture (OR 1.92) \[[@CR58]\]. However, increased fracture risk persists after correction for falls \[[@CR59]\].

Diabetes treatment may also modulate fracture risk \[[@CR60]\]. Metformin and sulfonylureas have neutral or slightly protective associations with fracture risk \[[@CR60], [@CR61]\]. It is possible that metformin increases osteoblast activity through Runt-related transcription factor 2 (Runx2) signalling. Thiazolidinediones (TZDs, glitazones) activate peroxisome proliferator-activated receptor gamma (PPARγ) which decreases insulin resistance. Activation of PPARγ suppresses IGF-1 expression in bone and drives differentiation of mesenchymal stem cells to adipocytes rather than to osteoblasts \[[@CR62]\]. TZD use is associated with increased fracture risk---the ADOPT study reported cumulative incidence of fractures of 15.1% with rosiglitazone versus 7.3% with metformin \[[@CR63]\]. Sodium--glucose cotransporter-2 (SGLT2) inhibitors have been associated with increased fracture risk \[[@CR64]\], possibly through increased renal phosphate reabsorption leading to increased parathyroid hormone (PTH) and increased bone resorption \[[@CR65]\]. Gut peptides such as GLP-2 decrease turnover in response to feeding, and there has been interest in the possible bone effects of GLP-1 analogues and dipeptidyl peptidase 4 (DPP-4) inhibitors in diabetes treatment. So far, there is no clear evidence of an effect on fracture risk \[[@CR66]\]. Fracture risk is higher in people treated with insulin than with oral agents, but this may reflect insulin use as a marker of longer duration of disease, poorer control and more microvascular complications rather than a direct biological effect.

Fracture Risk Assessment and Osteoporosis Treatment in T2DM {#Sec7}
===========================================================

Because BMD is increased in T2DM, and there are disease-specific risk factors such as microvascular disease and collagen glycation, standard fracture risk assessments using DXA and clinical risk factors (including FRAX) underestimate fracture risk in T2DM \[[@CR67]\]. Inadequate or inaccurate risk assessment is reflected in the observation that people with diabetes are less likely to be prescribed bisphosphonates than those without diabetes \[[@CR68]\]. This may be partly due to underestimation of risk by assessment tools, but also because clinicians do not recognise that people with diabetes are at risk of fracture, so do not assess their risk or treat.

Although the pathophysiology of fracture in T2DM differs from postmenopausal osteoporosis, (particularly in that bone turnover is low in T2DM), osteoporosis treatments do reduce fracture in T2DM. In post hoc analysis of the FIT alendronate and HORIZON zoledronic acid trial, fracture reduction was similar in participants with and without diabetes \[[@CR69]\]. Teriparatide and sclerostin antibodies increase BMD in Zucker diabetic rats, but the rats' bone phenotype is different from human T2DM, and there is not yet available information on these drugs in humans with T2DM \[[@CR70], [@CR71]\].

Summary and Discussion {#Sec8}
======================

Obesity in adults is protective against some fractures, particularly hip fractures. However, some fractures, such as ankle and humerus are more common in obesity, and the prevalence of low-trauma fractures is similar in obese and non-obese women. BMD in obese people is higher at all sites, bone turnover is lower, and bone strength measures suggest that obesity is favourable for bone strength, but bone strength does not seem sufficiently increased to protect against all fractures. Therefore, explanations for the fracture pattern in obesity need to consider other factors such as load-to-strength ratio, soft tissue padding, muscle function and falls. Finite element models incorporating patient-specific factors such as height, weight, soft tissue thickness and quantitative gait assessment with bone physical measurements may offer a route of investigation for these potential contributors.

There are many possible mechanisms acting on bone metabolism in obesity, such as adipokines and gut hormones. Some of these are potential therapeutic targets for the treatment of osteoporosis in obese and non-obese people.

Type 2 diabetes is associated with increased BMD and lower bone turnover but increased overall risk of fracture and hip fracture. Some of the mechanisms acting to increase BMD in obesity are likely to be relevant in T2DM, but the pathophysiology of bone fragility in T2DM is not yet clearly understood. Additional influence of AGEs on bone matrix and complications of diabetes are likely to contribute to the increased fracture risk, and AGE markers might be of value in further research and clinical assessment. If glucose exposure and diabetes complications are major contributors, the most effective strategy to reduce fracture risk may be to improve glycaemic control. Fracture risk in T2DM is under-recognised, under-estimated and undertreated, but anti-resorptives do seem to be effective in fracture prevention. If diabetes bone disease is a low-turnover state, it would be interesting to see whether it responds well to anabolic bone agents or whether the underlying pathology impairs the anabolic response.

As our populations become older and more obese, understanding the interactions of obesity, T2DM and fracture is becoming a pressing need to reduce the societal and individual costs of fracture.
